Amgen to build first-of-its-kind biomanufacturing plant in the US

10 Apr 2018

Revolutionary, innovative plant offers greater flexibility, speed and efficiency.

Amgen has announced plans to build a new state-of-the-art next-generation biomanufacturing plant at its campus in West Greenwich, RI. The new plant, the first of its kind in the US, will employ Amgen's proven next-generation biomanufacturing capabilities and manufacture products for the US and global markets.

Amgen to build first-of-its-kind biomanufacturing plant in the US

A next-generation biomanufacturing plant incorporates multiple innovative technologies into a single facility, and therefore is built in half the construction time with approximately one half of the operating cost of a traditional plant. Next-generation biomanufacturing plants require a smaller manufacturing footprint and offer greater environmental benefits, including reduced consumption of water and energy and lower levels of carbon emissions.

"Amgen has three decades of experience in biologics manufacturing, and we are proud of our track record of providing a reliable supply of high-quality medicines for patients around the world," said Esteban Santos, executive vice president of Operations at Amgen. "We are pleased to build the first commercial scale, next-generation biomanufacturing plant in the US, leveraging Amgen's capabilities and incorporating the latest technologies."

A comprehensive evaluation of global locations was conducted to select the location. Following recent US federal tax reform, which provides company incentives to invest in innovation and advanced technologies, Amgen made the decision to locate the new plant in the US. Rhode Island was selected based on the historical success of the Amgen West Greenwich manufacturing facility, its capabilities and talented workforce, and quality of living for staff and potential to grow. The biomanufacturing plant will be built on the current Amgen Rhode Island 75-acre campus and is expected to create approximately 150 additional highly-skilled manufacturing positions and approximately 200 construction and validation jobs.

"I am thrilled that Amgen is planning to expand and bring new, highly skilled jobs to Rhode Island and further enhance the State's life sciences community and manufacturing expertise," said Rhode Island Governor Gina Raimondo. "We welcome Amgen's future healthcare advancements for patients around the world that will come from this new biomanufacturing plant."

Amgen opened its first next-generation biomanufacturing plant in Singapore in 2014. This type of plant offers a highly flexible, modular design which can be replicated in future facilities, which enables Amgen to increase production capabilities reliably with greater speed, productivity and flexibility. Within the plant, the equipment is portable, smaller and disposable, which provides greater flexibility and speed when manufacturing different medicines simultaneously. This eliminates costly and complex retrofitting inherent in standard facilities and allows Amgen to respond to changing demands with increased agility, ultimately impacting the speed at which a medicine is available for patients.

"We are excited that Amgen Rhode Island was chosen as the location to build the new biomanufacturing plant," said Tia Bush, vice president of Operations at Amgen Rhode Island. "It is a testament to our skilled, dedicated workforce and Amgen's continued presence in Rhode Island, which will enable ongoing collaborations with local academic institutions and the broader Rhode Island community."

Read More

Related news

TraceLink unveils Product Information Manager for its digital information sharing platform

TraceLink unveils Product Information Manager for its digital information sharing platform

12 Jul 2018

Product Information Manager addresses a broad range of use cases, beginning with saleable returns.

Read more 
Stability studies trends

Stability studies trends

10 Jul 2018

Dr Ramesh Jagadeesan, Sr. Director - Analytical Development at Recipharm, speaks to CPhI Online on the trends and challenges involved with conducting stability studies for firms that supply to multiple countries, and the advantages of using a contracto...

Read more 
Recipharm launches standalone serialisation service

Recipharm launches standalone serialisation service

5 Jul 2018

Company will be able to add 2D codes, human-readable text and tamper evidence to pre-packed medicines using existing equipment across its facilities.

Read more 
CPhI Worldwide opens entries for 15th Annual Pharma Awards

CPhI Worldwide opens entries for 15th Annual Pharma Awards

5 Jul 2018

Winners will be announced live at the Gala Ceremony in Madrid with over 500 of Pharma’s top executives.

Read more 
Catalent to acquire Juniper Pharmaceuticals

Catalent to acquire Juniper Pharmaceuticals

5 Jul 2018

$133 million deal adds European Early Development Center of Excellence to global network.

Read more 
Insights in lyophilization science

Insights in lyophilization science

4 Jul 2018

The latest developments in process development, nucleation control, scale-up of freeze drying cycles and development in lyophilization technology.

Read more 
Bosch to sell its packaging business

Bosch to sell its packaging business

4 Jul 2018

Packaging technology is not a core Bosch business.

Read more 
Plasticell leads gene therapy manufacturing consortium

Plasticell leads gene therapy manufacturing consortium

3 Jul 2018

Consortium to develop advanced technologies for the manufacturing of ex vivo gene therapies.

Read more 
Forté Pharma strengthens its leadership in weight control in France

Forté Pharma strengthens its leadership in weight control in France

1 Jul 2018

Company consolidated as one of the leading laboratories in weight control thanks to the development of its existing range and new launches.

Read more 
I Holland woos exhibition visitors with new tabletting technologies

I Holland woos exhibition visitors with new tabletting technologies

28 Jun 2018

Company's Wear Indicator Layer attracts the most attention.

Read more